Drug factory · FDA FEI 3005254981
MSN Laboratories Private Limited
Sy. No. 317, 320, 321, 322, 323, 604 & 605, Rudraram (Village), Patancheru (Mandal), , Sangareddy District, India
Problems found, fixed voluntarily at FDA's last inspection, Aug 14, 2026.
Voluntary Action Indicated: inspectors found problems, but not serious enough for FDA to take action. The company is expected to fix them.
6 drug inspections on record since 2012: 3 with no problems, 3 with problems fixed voluntarily, 0 with FDA action.
What it does, for whom
| Drug | Role | For | NDC |
|---|---|---|---|
| Dapagliflozin | Makes the active ingredient and tests it | Cipla USA., Inc. | 69097-388, 69097-389 |
| Posaconazole | Makes the active ingredient | Lupin Pharmaceuticals, Inc. | 70748-258 |
FDA inspection history
| Ended | Result | Program | Problems noted |
|---|---|---|---|
| Aug 14, 2026 | Problems found, fixed voluntarily | Drug Quality Assurance | — |
| Mar 31, 2023 | No problems found | Drug Quality Assurance | — |
| Dec 20, 2019 | No problems found | Drug Quality Assurance | — |
| Mar 9, 2018 | Problems found, fixed voluntarily | Drug Quality Assurance | — |
| Feb 6, 2015 | Problems found, fixed voluntarily | Drug Quality Assurance | — |
| Mar 9, 2012 | No problems found | Drug Quality Assurance | — |
Registered with FDA for: analysis; api manufacture.